Since both the endocannabinoid/CB1R system and iNOS could contribute to PF initiation and progression (Figure 2), we began pharmacological treatment at the fibrosis initiation phase for antifibrotic efficacy testing (Figure 2A). The gene discussed is NOS2; the disease is pemphigus foliaceus.